Unit

UNIT 7.15 Overview of Experimental Models of the Blood-Brain Barrier in CNS Drug Discovery

  1. Alan M. Palmer1,
  2. Mohammad S. Alavijeh2

Published Online: 8 OCT 2013

DOI: 10.1002/0471141755.ph0715s62

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Palmer, A. M. and Alavijeh, M. S. 2013. Overview of Experimental Models of the Blood-Brain Barrier in CNS Drug Discovery. Current Protocols in Pharmacology. 62:7.15.1–7.15.30.

Author Information

  1. 1

    Cerebroscience, London, United Kingdom

  2. 2

    Pharmidex Pharmaceutical Services, London, United Kingdom

Publication History

  1. Published Online: 8 OCT 2013

Abstract

The blood-brain barrier (BBB) is a physical and metabolic entity that isolates the brain from the systemic circulation. The barrier consists of tight junctions between endothelial cells that contain egress transporters and catabolic enzymes. To cross the BBB, a drug must possess the appropriate physicochemical properties to achieve a sufficient time-concentration profile in brain interstitial fluid (ISF). In this overview, we review techniques to measure BBB permeation, which is evidenced by the free concentration of compound in brain ISF over time. We consider a number of measurement techniques, including in vivo microdialysis and brain receptor occupancy following perfusion. Consideration is also given to the endothelial and nonendothelial cell systems used to assess both the BBB permeation of a test compound and its interactions with egress transporters, and computer models employed for predicting passive permeation and the probability of interactions with BBB transporters. Curr. Protoc. Pharmacol. 62:7.15.1-7.15.30. © 2013 by John Wiley & Sons, Inc.

Keywords:

  • blood-brain barrier;
  • brain disorders;
  • drug discovery;
  • neuroscience;
  • in vivo microdialysis;
  • MDCK cells;
  • receptor occupancy;
  • brain medicines;
  • brain disorders